Treatment Options for CLL: An Expert RoundtableJennifer R. Brown
EP: 1.Current Front-Line Treatment Options for CLL in 2023 EP: 2.Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA EP: 3.Strategies for Managing Treatment-Naïve CLL with High-Risk Features EP: 4.Impact of Off-Target AEs and Treatment Resistance on Evolving...
Emerging Agents Signal Promising Opportunities to Expand Treatment Options for CLL Author(s): Megan HollaschIn Partnership With: Anthony Mato, MD, MSCE, discusses the relapsed refractory setting compared with the frontline setting and promising agents such as pirtobrutinib and zanubrutinib....
Jennifer Woyach, MD, an associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer CenterJames, discusses the frontline options for the treatment of patients with chronic lymphocytic leukemia (CLL).
CALQUENCE® (acalabrutinib) is a BTK inhibitor indicated for the treatment of adult patients with R/R Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
Expert opinion: Treatment options for CLL have increased significantly with the introduction of the BTK inhibitors, PI3K inhibitors, BCL2 inhibitors, and novel anti-CD20 monoclonal antibodies. In this scenario, predictive biomarkers can assist physicians in optimizing treatment tailoring. Furthermore, ...
So for CLL, we work with all of the CLL providers, whether it be inpatient or outpatient, but I think the majority of the treatments are in the outpatient setting. So that's where we really kind of shine with our help there. Mainly in the clinics, we'll see all of the new ...
Here are some of the options your doctor will consider. You may also take other types of medicines to help prevent complications, such as to prevent infections while you’re going through treatment. CLL Treatments Chemotherapy for CLL These drugs disrupt the life cycle of cancer cells. They dam...
EP: 1.Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options EP: 2.Clinical Implications and Unmet Needs in CLL BTKi Therapies EP: 3.Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma EP: 4.Integrating Emerging BTKi Therapies Into Current Treatment Guidelines EP:...
Navigating 2L Treatment Options in CLL EP: 12.Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications EP: 13.Management Strategies for BTKi-Related CVAEs in CLL EP: 14.Updates in CLL Treatment Strategies with Noncovalent BTKis EP: 15.Looking Ahead: Novel Therapies and ...